BeOne Medicines stock

ONC · NASDAQ · USD

Compare BeOne Medicines
$416.54Change from previous close: +0.14%Absolute change: +$0.58

Close · November 13, 2026

Price history

+13.08% over the period

1 year: from $368.36 (November 13, 2025) to $416.54 (November 13, 2026), +13.08%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$416.54
October 30, 2026$370.33
September 30, 2026$365.94
August 31, 2026$359.58
July 31, 2026$316.01
June 30, 2026$284.97
May 29, 2026$287.92
April 30, 2026$295.27
March 31, 2026$296.97
February 27, 2026$316.99
January 30, 2026$340.38
December 31, 2025$303.81
November 28, 2025$340.61
November 13, 2025$368.36

At a glance

  • The company

    Oncology company discovering and developing cancer treatments including commercial-stage drugs and clinical-stage candidates targeting blood cancers, solid tumors, and other malignancies

  • Latest results

    Quarter to September 30, 2026 · EPS $3.28 (estimate $1.89)

TickerLandia's take on BeOne Medicines

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$253.95
52-wk high$424.73

−1.93% from the 52-week high

Analysts · 27 analysts

Average target$469.23+12.65% vs. price

Buy 26 · Hold 1 · Sell 0 · Strong buy

TickerLandia Fingerprint: BeOne Medicines

Compared with similar companies: very strong momentum.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

BeOne Medicines is pricier than similar companies

BeOne Medicines's P/E (trailing 12 months): 53.4, +36% against the median of a group of 6 similar companies (39.3).

Compared with 6 similar companies

BeOne Medicines's metrics compared with similar companies
MetricBeOne MedicinesPosition in the groupBand
P/E (trailing 12 months)53.4High
Forward P/E38.9High
Operating margin17.8%Middle
ROE18.4%High
Debt/equity0.35Middle

Grey band: the middle half of the group; tick: the median; dot: BeOne Medicines. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$1.71B

Latest quarter · Q2 2026

Net income

$237.01M

Latest quarter · Q2 2026

Quarterly net margin

13.9%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$47.58B
P/E
53.4
EPS
$7.80
Volume
345.46K
Daily trading
€164.64M
Dividend yield
0.00%

How BeOne Medicines is changing

All results
  • Revenue grew 76.8% a year on average over the last 5 years

  • Operating margin rose from −126.4% to 8.4%

  • Shares outstanding up 35.9% in 5 years

Returns

BeOne Medicines returns

$1,000 invested in BeOne Medicines 5 years ago, on November 15, 2021, would be worth $1,089 today: +8.94% in total, +1.73% per year. This is the price return only: dividends are excluded.

PeriodBeOne MedicinesS&P 500$1,000 becomes
1 month+19.33%−3.12%$1,193
6 months+31.59%+1.58%$1,316
Year to date+37.11%+10.46%$1,371
1 year+13.08%+12.23%$1,131
3 years+109.47%+71.41%$2,095
5 years+8.94%+61.48%$1,089
10 years+1,088.42%+249.40%$11,884

Over the last 6 months it has done better than 70% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

BeOne Medicines: technical analysis

BeOne Medicines is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 1.8% below its all-time closing high ($424.00, November 10, 2026).

Trend
Upward
RSI (14 sessions)
67
Between 30 and 70
vs 200-session average
+27.07%

Support and resistance

Price areas where BeOne Medicines has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price$416.54
  3. Support$384.63−7.66%3 touches, last on October 21, 2026
  4. Support$372.50−10.57%3 touches, last on September 30, 2026
  5. Support$350.35−15.89%2 touches, last on November 3, 2026

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.67
Volatility (60 sessions, annualised)
32.0%
Largest fall in the last year
−30.90%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

BeOne Medicines: seasonality

Average monthly price change over 11 years

+8.4%Jan+2.8%Feb−2.9%Mar+1.9%Apr−2.0%May+1.0%Jun+14.4%Jul+4.4%Aug+6.5%Sep−0.3%Oct+6.4%Nov−4.4%Dec

Over the last 11 years, the strongest month for BeOne Medicines has been July: +14.37% on average, positive in 9 years out of 11. The weakest has been December: −4.37% on average, positive in 3 years out of 10. November, the current month, has been positive in 6 years out of 10 (+6.37% on average).

Show chart data
MonthAverageMedianPositive years
January+8.37%+13.40%6 of 10
February+2.75%+4.81%6 of 10
March−2.93%−4.05%4 of 11
April+1.88%−1.30%4 of 11
May−1.96%−3.31%4 of 11
June+1.04%−1.02%5 of 11
July+14.37%+10.93%9 of 11
August+4.36%+2.13%7 of 11
September+6.48%+7.31%7 of 11
October−0.30%+1.20%6 of 11
November+6.37%+3.23%6 of 10
December−4.37%−6.37%3 of 10

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

BeOne Medicines and its competitors

BRUKINSA and TEVIMBRA are the medicines most closely associated with BeOne Medicines AG, which was known as BeiGene until its renaming in May 2025. BRUKINSA, a BTK inhibitor, is used against several blood cancers, while TEVIMBRA is an anti-PD-1 antibody that treats solid tumors and blood cancers. The pipeline includes candidates such as sonrotoclax, a Bcl-2 inhibitor, and zanidatamab, a HER2-targeted bispecific antibody. Partners include Amgen, BMS, Novartis and Luye Pharmaceutical, and the company holds an agreement with the U.S. government on access to cancer medicines.

Headquarters
Basel, Switzerland
Employees
12,000
Founded
2010
Chief executive
John Oyler
BeOne Medicines and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
BeOne MedicinesONC$47.58B17.8%53.4+31.59%
Royalty PharmaRPRX$39.85B64.4%45.3+30.16%
argenxARGX$60.37B31.9%33.3+19.60%
Revolution MedicinesRVMD$37.27B-853.0%—+14.91%
Roivant SciencesROIV$28.64B-3,226.3%—+35.28%
InsmedINSM$26.58B-41.7%—+2.69%

Same industry or related industries, similar size. Compare BeOne Medicines with its competitors · Full profile